Wir verwenden Cookies und Analyse-Tools, um die Nutzerfreundlichkeit der Internet-Seite zu verbessern und für Marketingzwecke. Wenn Sie fortfahren, diese Seite zu verwenden, nehmen wir an, dass Sie damit einverstanden sind. Zur Datenschutzerklärung.
Rufinamide
CHF 43.00
Auf Lager
SKU
PCGCOP90S90
1 Verfügbar 
Geliefert zwischen Mo., 17.11.2025 und Di., 18.11.2025
Details
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai. Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. Its official FDA-approved labeling does not mention use in the treatment of partial seizures inasmuch as clinical trials submitted to the FDA were marginal. However, several recent clinical trials suggest that the drug has efficacy for partial seizures It is marketed under the brand name Banzel. It is also marketed in the European Union under the brand name Inovelon.
Weitere Informationen
- Allgemeine Informationen
- Editor Lambert M. Surhone, Miriam T. Timpledon, Susan F. Marseken
- Titel Rufinamide
- Format Fachbuch
- EAN 9786131020902
- Größe H220mm x B220mm
- Genre Medizin
- Anzahl Seiten 96
- Herausgeber Betascript Publishing
- GTIN 09786131020902
Bewertungen
Schreiben Sie eine Bewertung
